Drug Trial Radar · NCT07104162
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 16, 2025
Primary completion
Sep 4, 2026
Study completion Sep 4, 2026
Sponsor
- Lead sponsor
- Qpex Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Shionogi Inc.; Biomedical Advanced Research and Development Authority
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam (S-649228) in Participants with Renal Impairment
Conditions
- Bacterial Infections
Interventions
Cefiderocol/XeruborbactamDrug
A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) by participant and by groupTime frame: 11-22 days (+/- 2)
- Number of participants with changes from baseline in safety parametersTime frame: 11-22 days (+/- 2)
- Maximum plasma concentration measurements by subject and by group (Cmax)Time frame: 11-22 days (+/- 2)
- Time to maximum plasma concentration (Tmax)Time frame: 11-22 days (+/- 2)
- Area under the plasma concentration versus time curve (AUC)Time frame: 11-22 days (+/- 2)
- Cumulative amount of drug excreted as unchanged in the urine (Aeu)Time frame: 11-22 days (+/- 2)
- Cumulative amount of drug excreted as unchanged in the dialysate (Aed)Time frame: 11-22 days (+/- 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Clinical Pharmacology
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.